CTLA4 and neoplasm: These observations are promising since they suggest that CTLA-4 expressed at the tumor-cell surface might be itself a target of immune checkpoint inhibitors, and might also be a candidate biomarker for immunotherapy, which is urgently needed to provide robust tools to select patients who might benefit from this new therapeutic strategy.